Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

The appointment comes as IceCure is experiencing strong commercial momentum for ProSense(R) in the United States and globally following U.S. Food and Drug Administration ("FDA") c ...

IceCure Medical Ltd. announced positive top-line results from its ICESECRET clinical trial of its ProSense cryoablation ...

IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with ...

While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires ...

7-partial-nephrectomy-0516 Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a ...

January 19, 2012 — Multisite cryoablation of metastatic epithelial ovarian cancer is well tolerated, has a 5-year overall survival rate of 30%, and is cost effective, compared with other forms of ...

In a propensity score-based study, prostate cryoablation added to androgen deprivation therapy (ADT) improved failure-free survival and survival without castration-resistant disease compared with ADT ...

Cryoablation is a fairly new treatment being used to treat small cancer tumors. Could we soon see it offered as an alternative to traditional breast cancer surgeries? There isn’t a day that goes by ...

Please provide your email address to receive an email when new articles are posted on . Cryoablation may be an effective primary treatment option for women with low-risk breast cancer, according to ...